

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司

SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)

ANNOUNCEMENT

PROPOSED ISSUE OF THE CORPORATE BONDS

In order to satisfy the actual needs of replenishment of working capital, investment and standing funds, adjust financing structure and lower the financing cost, on 27 April 2023, the Board resolved to propose the issue of the Corporate Bonds in the PRC.

According to the laws of the PRC and the Articles of Association, the proposed issue of the Corporate Bonds is subject to the approval of the Shareholders by way of a special resolution and the approval from the relevant PRC regulatory authorities.

The proposed issue of the Corporate Bonds may or may not proceed, and the Shareholders and investors should therefore exercise caution in dealing in the shares of the Company.

A circular of the Company containing, among other things, detailed information of the proposed issue of the Corporate Bonds will be despatched to the Shareholders in due course.

Proposed Issue of the Corporate Bonds

In order to satisfy the actual needs of replenishment of working capital, investment and standing funds, adjust financing structure and lower the financing cost, on 27 April 2023, the Board resolved to propose the issue of the Corporate Bonds in the PRC.

According to the laws of the PRC and the Articles of Association, the proposed issue of the Corporate Bonds is subject to the approval of the Shareholders by way of a special resolution and the approval from the relevant PRC regulatory authorities.

Particulars of the issue of the Corporate Bonds, if it proceeds, are as follows:

- Issue size: Registered amount: RMB15 billion. A proposal will be presented to the general meeting for authorizing the Board or its authorized person(s) to determine the specific issue size, issue tranches and type of bonds based on the actual needs of the Company and the market conditions prevailing at the time of issue within the aforesaid range.
- Term of the issue: The term shall not exceed 10 years (inclusive). For the type of bonds, it shall be either of a single term, or of a combination of multiple terms. A proposal will be presented to the general meeting for authorizing the Board or its authorized person(s) to determine specific terms of maturity based on the actual needs of the Company and the market conditions prevailing at the time of issue within the aforesaid range.
- Issue method: The Corporate Bonds shall be issued publicly to professional investors.
- Underwriting method: Standby commitment underwriting by the lead underwriters
- Interest rate: A proposal will be presented to the general meeting for authorizing the Board or its authorized person(s) to determine the nominal interest rate and the payment method based on the funding needs of the Company and the market interest rate and according to the market conditions prevailing at the time of issue and by way of market enquiry, after arm's length negotiation with the lead underwriter.
- Use of proceeds: The proceeds from the issue of the Corporate Bonds is proposed to use for repaying the debts of the Company, replenishing the working capital of the Company, project construction, equity investment and other uses in compliance with relevant requirements of the laws and regulations. A proposal will be presented to the general meeting for authorizing the Board or its authorized person(s) to determine the specific use of proceeds.
- Guaranty: The Corporate Bonds are unsecured bonds.
- Listing place: Upon completion of the issue of the Corporate Bonds, the Company will apply for listing of the Corporate Bonds on the Shanghai Stock Exchange. A proposal will be presented to the general meeting for authorizing the Board or its authorized person(s) to deal with listing and trading matters in accordance with the relevant regulations of the Shanghai Stock Exchange.
- Guarantee measures for repayment: A proposal will be presented to the general meeting for authorizing the Board or its authorized person(s) to adopt a variety of guarantee measures for repayment based on the relevant provisions of Bond Entrusting Agreements and Rules of Procedures for Bondholders' Meetings and other documents in the event that the Company expects that it is unable to repay the principal and

interests of the Corporate Bonds as scheduled, or is unable to repay the principal and interests of the Corporate Bonds when they become due, so as to effectively safeguard the interest of the bondholders.

Term of validity of the resolution: The term of validity of the resolution passed at the general meeting in relation to the proposed issue of the Corporate Bonds shall be 36 months from the date of approval at the general meeting. If the Board or its authorised person(s) has resolved to issue or partly issue during the valid period of authorization, and the Company has obtained the approval or permit of the issuance from the regulatory authorities in the valid period of the resolution, the Company may complete the relevant issuance during the valid period of such approval or permit.

Subject to the Shareholders' approval at the general meeting, the Board or the person(s) authorised by the Board, will be authorised to do the following, including but without limitation to:

- (1) in accordance with the laws and regulations, relevant provisions of regulatory authorities and the resolutions adopted at the general meeting of the Company, as well as the Company and the bond market's actual situation, to determine and adjust the specific plan of the issue of the Corporate Bonds, including but not limited to the issue size of the Corporate Bonds, issue method (including whether to issue in tranches, amount for each tranche, etc.), specific terms of maturity and the issue size of each maturity type, whether to include redemption provision or put-back provision, interest rate of the bonds, principal and interest repayment, use of the proceeds, guaranty arrangement, guarantee measures for repayment, specific purchase methods, specific placing arrangements, bond listing, and all matters related to this issue plan;
- (2) to determine the engagement of professional agents to assist the Company in handling the matters related to the application and listing for the Corporate Bonds;
- (3) to formulate, approve, sign, amend and announce all the legal documents regarding the issue of the Corporate Bonds;
- (4) to select the bond trustee, sign the bond trustee management agreement and formulate the rules of bondholders' meeting;
- (5) upon the completion of the issue of the Corporate Bonds, to take the actions regarding the listing of the Corporate Bonds;
- (6) if there is any change on the opinions of the regulatory authorities, policies or market conditions, to make suitable adjustments on the matters of the issue of the Corporate Bonds, or to decide whether to proceed the issue of the Corporate Bonds based on the actual situations, except for the matters which are subject to the Shareholders' approval in accordance with the relevant laws, regulations and the Articles of Association; and
- (7) to deal with all other matters relating to the issue of the Corporate Bonds.

The Board will present resolution to the general meeting for authorizing the Board and agreeing the Board in turn to authorize Mr. Yu Qingming, the Chairman of the Board and an executive Director, to be the authorized person of this issue, and to represent the Company to deal specifically with the issue and listing related matters, in accordance with the resolutions of the general meeting. The foregoing authorization shall be valid within 36 months from the date of approval at the general meeting.

The Board believes that the proposed issue of the Corporate Bonds will provide the Company with a source of medium-term to long-term funding at an interest rate of the issue which has certain advantaged under favarouble market conditions. The Board considers that the proposed issue of the Corporate Bonds will lower the Company’s costs of borrowings and improve the debt structure of the Company.

A circular of the Company containing, among other things, detailed information of the proposed issue of the Corporate Bonds will be despatched to the Shareholders in due course.

The proposed issue of the Corporate Bonds may or may not proceed, and the Shareholders and investors should therefore exercise caution in dealing in the shares of the Company.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms shall have the meanings set out below:

“Articles of Association”	the articles of association of the Company
“Board”	the board of directors of the Company
“Company”	Sinopharm Group Co. Ltd., (國藥控股股份有限公司), a joint stock company incorporated in the PRC with limited liability and whose H shares are listed and traded on The Stock Exchange of Hong Kong Limited
“Corporate Bonds”	corporate bonds with a registered amount of RMB15 billion proposed to be issued by the Company
“Director(s)”	the director(s) of the Company
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“PRC”	the People’s Republic of China which, for the purpose of this announcement, excludes Hong Kong, the Macau Special Administrative Region and Taiwan Region
“RMB”	Renminbi, the lawful currency of the PRC
“Shareholders”	the shareholders of the Company

By order of the Board
Sinopharm Group Co. Ltd.
Yu Qingming
Chairman

Shanghai, the PRC

27 April 2023

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Ma Ping, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.

**The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”*